Chacruna (Psychotria viridis)
What Is Chacruna?
Chacruna is catalogued in the Materia Medica under the binomial Psychotria viridis, a plant of the Rubiaceae family, native to the tropics, especially the Amazon. The material in circulation is leaf (ethnobotanical) — leafy growth taken above ground. Most people search for it simply as Chacruna; suppliers, pharmacopoeias and interaction databases list it as Psychotria viridis, and matching the two is the first step in identifying what is actually in a product. In the hand it reads as green, tannic, faintly grassy — a practical marker of freshness and correct identification.
The written history of Chacruna begins with household and practitioner use — recipes, harvesting notes and cautions passed between regions — and only much later with laboratory description of what the leaf (ethnobotanical) contains. Beyond its practical use it carries cultural associations — the 'light-giving' leaf paired with the caapi vine.
Today most searches for Chacruna come from people reading about stress relief and weight management, or checking how it sits alongside a medication they already take. The use most often documented in the literature is DMT is under formal investigation for depression and end-of-life distress, followed by central to ceremonial traditions with legal religious protection in Brazil and some US contexts.
How Does Chacruna Work?
Chacruna works as a mixture rather than a single isolated compound, and its profile is usually described by the class of constituents present in leaf (ethnobotanical) rather than by one marker molecule.
The older understanding of Chacruna is procedural rather than molecular — which part to take, in what season, and in what medium — and modern constituent work has largely been an attempt to explain why those procedures were chosen.
Published research is limited, leaning on small trials, laboratory work and animal models, and this profile cites 1 source. Reported findings centre on leaf contains roughly 0.1–0.66% N,N-dimethyltryptamine by dry weight, with content varying by cultivar, leaf age and harvest time. Where research exists, it examines DMT is under formal investigation for depression and end-of-life distress, central to ceremonial traditions with legal religious protection in Brazil and some US contexts and model compound for 5-HT2A receptor research. These are areas of study, not established outcomes, and results differ by preparation and dose.
How the plant is prepared changes what you actually get. Its constituents move readily into alcohol — so a preparation made in another medium will not carry the same fraction of the plant, which is why traditional recipes specify one over another.
What makes Chacruna distinct is the combination rather than any one molecule: the same compound classes appear in other botanicals, but their ratio here — and the leaf (ethnobotanical) they are drawn from — is what the traditional and research literature both describe.
Because these constituents are processed by the same pathways that handle many medicines, Chacruna is documented as interacting with ssris / snris, mao inhibitors and antipsychotics. That is a question of shared metabolism rather than of potency, and it is the main reason the plant is listed in interaction references at all.
Dose, plant part and growing conditions all shift the constituent profile, so two products carrying the name Chacruna can differ substantially; this is why reference entries specify leaf (ethnobotanical) and, where they exist, standardisation markers.